Related Experiment Videos
Dose granisetron remain effective over multiple cycles? The Granisetron Study Group
1Academisch Ziekenhuis Utrecht, The Netherlands.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1992
Summary
Intravenous granisetron effectively controlled chemotherapy-induced nausea and vomiting for most patients over multiple cycles. Both 40 micrograms/kg and 3 mg doses demonstrated similar efficacy and good tolerability with repeated use.
Area of Science:
- Oncology
- Pharmacology
- Clinical Therapeutics
Background:
- Chemotherapy often causes significant nausea and vomiting.
- Granisetron is an antiemetic used for prophylaxis.
- This study evaluated long-term granisetron use in chemotherapy patients.
Purpose of the Study:
- To assess the efficacy and tolerability of intravenous granisetron for prophylaxis of chemotherapy-induced nausea and vomiting (CINV).
- To evaluate granisetron's effectiveness over multiple chemotherapy cycles.
- To compare two dosing regimens: 40 micrograms/kg and 3 mg.
Main Methods:
- Two studies involved 574 and 335 patients receiving intravenous granisetron for CINV prophylaxis.
- Patients received either 40 micrograms/kg or 3 mg of granisetron per cycle.
- Efficacy was assessed by complete protection from symptoms for 24 hours post-chemotherapy.
Main Results:
- Approximately 60% of patients achieved complete symptom protection for up to 8 cycles with either regimen.
- Efficacy remained around 70% for moderately emetogenic regimens.
- A decrease in efficacy was noted with high-dose cisplatin over 5 cycles, potentially linked to gender risk factors.
Conclusions:
- Intravenous granisetron demonstrated sustained efficacy and good tolerability over repeated chemotherapy cycles.
- Both 40 micrograms/kg and 3 mg doses were equally effective in managing CINV.
- Some reduction in effectiveness was observed with cumulative high-dose cisplatin treatment.